(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...

A preclinical study shows that combining KRASG12D inhibition with CTLA-4 blockade dismantles a TGF-beta-driven regulatory T ...

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) plays a crucial role in maintaining peripheral immune tolerance, but its mechanisms of action are highly complicated. Here, through the generation ...

A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...

LAS VEGAS, Dec. 16, 2024 /PRNewswire/ -- CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected ...

Discover the latest articles and news in related subjects. Although acute myeloid leukemia (AML) can be cured after standard chemotherapy and stem cell transplantation (SCT), relapse after the first ...

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an immunogenic protein receptor that is expressed almost exclusively on CD4+ and CD8+ T cells. It plays a crucial role in the homeostasis of ...

CTLA-4 is a protein on immune cells that slows the immune response. Mesothelioma cells use CTLA-4 to avoid immune detection. CTLA-4 inhibitor drugs like Yervoy (ipilimumab) and Imjudo (tremelimumab) ...

T cells are the 'foot soldiers' that fight cancer inside the body. Cancer cells can fight the foot soldiers back by pushing a brake on the T cells that will turn them off. This 'brake' is a molecule ...

T cells are the 'foot soldiers' that fight cancer inside the body. Cancer cells can fight the foot soldiers back by pushing a brake on the T cells that will turn them off. This 'brake' is a molecule ...